<DOC>
	<DOCNO>NCT00592007</DOCNO>
	<brief_summary>The main purpose research study see add fulvestrant ( Faslodex ) erlotinib ( Tarceva ) effective patient stage IIIb/IV Non-Small Cell Lung Cancer .</brief_summary>
	<brief_title>Study Evaluating Addition Fulvestrant Erlotinib Stage IIIB/IV Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>Erlotinib oral drug able block endothelial growth factor receptor ( EGFR ) . EGFR stimulate cancer cell growth . Fulvestrant ( faslodex ) block estrogen hormone gain access tumor stimulate tumor cell grow . Both drug already approve FDA study combination . We study combination drug delay treatment failure . Lung cancer tumor males female sensitive estrogen . Only patient whose tumor express estrogen eligible trial . Estrogen sensitivity test previously remove tumor specimen .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<criteria>Estrogen progesterone receptor positive stage IIIb/IV nonsmall cell lung cancer Eligible patient stable disease erlotinib monotherapy FDA approve dos minimum duration erlotinib therapy 2 month 18 year old ECOG Performance Status â‰¤2 Adequate Organ Function Requirements Adequate coagulation function Postmenopausal status female patient require defined menstrual period 12 month surgical menopause All patient must sign write informed consent . Pregnant breastfeed woman enter study Patients currently receive another investigational drug Patients currently receive anticancer agent . Hormone replacement therapy allow stop 1 month prior entry study Patients uncontrolled infection . Patients receive less 100mg/day erlotinib Patients evidence progression 2 month erlotinib monotherapy . Patients history bleed diathesis ( i.e. , disseminate intravascular coagulation [ DIC ] , clot factor deficiency ) longterm anticoagulant therapy ( antiplatelet therapy ) . Patients history hypersensitivity active inactive excipients fulvestrant ( i.e . castor oil Mannitol ) . Patients opinion investigator may able comply safety monitoring requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Non Small Cell Lung Cancer</keyword>
	<keyword>Stage IIIB</keyword>
	<keyword>Stage IV</keyword>
	<keyword>Stable Erlotinib</keyword>
	<keyword>Exhibit Positivity Estrogen Progesterone Receptor</keyword>
</DOC>